Your browser doesn't support javascript.
loading
Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide.
Malard, Florent; Kröger, Nicolaus; Gabriel, Ian H; Hübel, Kai; Apperley, Jane F; Basak, Grzegorz W; Douglas, Kenneth W; Geraldes, Catarina; Jaksic, Ozren; Koristek, Zdenek; Lanza, Francesco; Lemoli, Roberto; Mikala, Gabor; Selleslag, Dominik; Worel, Nina; Mohty, Mohamad; Duarte, Rafael F.
Afiliación
  • Malard F; Centre Hospitalier et Universitaire de Nantes, Service d'Hématologie Clinique, Nantes, Université de Nantes, Centre d'Investigation Clinique en Cancérologie (CI2C), INSERM CRNCA UMR 892, Nantes, France.
Biol Blood Marrow Transplant ; 18(2): 314-7, 2012 Feb.
Article en En | MEDLINE | ID: mdl-22001752
Fludarabine and lenalidomide are essential drugs in the front-line treatment of non-Hodgkin lymphoma (NHL) and multiple myeloma (MM), respectively. Data suggests that fludarabine and lenalidomide therapy may have a deleterious effect on stem cell mobilization. In the European compassionate use program, 48 patients (median age 57 years) previously treated with fludarabine (median 5 cycles; range: 1-7 cycles) were given plerixafor plus granulocyte colony-stimulating factor (G-CSF) for remobilization following a primary mobilization attempt. The overall median number of CD34+ cells collected was 2.3 × 10(6)/kg (range: 0.3-13.4). The minimum required number of CD34+ cells (≥2.0 × 10(6)/kg) was collected from 58% of patients in a median of 2 days. Thirty-five patients (median age = 57 years) previously treated with lenalidomide (median 5 cycles; range: 1-10 cycles) were given plerixafor plus G-CSF for remobilization. The overall median number of CD34+ cells collected was 3.4 × 10(6)/kg (range: 1.1-14.8). The minimum required number of CD34+ cells (≥2.0 × 10(6) per kg) was collected from 69% of patients in a median of 2 days. In conclusion, salvage mobilization with plerixafor plus G-CSF is successful in the majority of patients with MM previously treated with lenalidomide. In fludarabine-exposed patients, only 58% of patients will achieve successful salvage mobilization with plerixafor plus G-CSF, suggesting the need for novel mobilization regimens algorithms in this subgroup of patients.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Talidomida / Vidarabina / Linfoma no Hodgkin / Fármacos Anti-VIH / Movilización de Célula Madre Hematopoyética / Trasplante de Células Madre de Sangre Periférica / Compuestos Heterocíclicos / Mieloma Múltiple / Antineoplásicos Tipo de estudio: Clinical_trials Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Biol Blood Marrow Transplant Asunto de la revista: HEMATOLOGIA / TRANSPLANTE Año: 2012 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Talidomida / Vidarabina / Linfoma no Hodgkin / Fármacos Anti-VIH / Movilización de Célula Madre Hematopoyética / Trasplante de Células Madre de Sangre Periférica / Compuestos Heterocíclicos / Mieloma Múltiple / Antineoplásicos Tipo de estudio: Clinical_trials Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Biol Blood Marrow Transplant Asunto de la revista: HEMATOLOGIA / TRANSPLANTE Año: 2012 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Estados Unidos